Galectin Therapeutics Inc. (GALT)

[DeepDive]

So, basically no additional response on P. from prolonging exposure, and at this regimen, too low response to be considered as viable treatment (although I would imagine some patients would like the lesser remedy at zero side effect, the biological have horrible s.e).

The PR was nicely spinned, and the market reacted like it should, we just lost a bunch of value priced for P. Drug.

Next stop is Sept., the dreaded top line for the short trial on Nash.

Prepare from some massive volatility, up or down, on results.

Long GALT.

btw, silence here suggests many gave up. My little position is a speculation long ago marked 0.